Iterum Reports Second Quarter 2018 Financial Results and Recent Highlights
14 août 2018 07h30 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing anti-infectives against multi-drug resistant...
Iterum Initiates SURE 1, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
09 août 2018 16h05 HE
|
Iterum Therapeutics plc
First of three planned Phase 3 pivotal trials now underway for Iterum’s oral antibiotic Oral sulopenem, if approved, could be the first antibiotic for uncomplicated urinary tract infections in over...
Otonomy to Present at Cowen and Company Health Care Conference
06 mars 2018 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, March 06, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that...
Otonomy Announces FDA Approval of OTIPRIO(R) for Acute Otitis Externa
02 mars 2018 11h55 HE
|
Otonomy, Inc.
SAN DIEGO, March 02, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that the...
Otonomy Provides Corporate and Product Pipeline Update
09 janv. 2018 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for diseases and disorders of the ear,...
Otonomy to Present at the J.P. Morgan Healthcare Conference
04 janv. 2018 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for diseases and disorders of the ear,...
Otonomy Announces Plan to Focus Resources on Development Programs
27 nov. 2017 16h30 HE
|
Otonomy, Inc.
Company to focus resources on completing OTIVIDEX™ clinical development to support U.S. regulatory approval for Ménière’s disease, and advancing multiple other programs addressing hearing loss and...
Otonomy to Present at Piper Jaffray Healthcare Conference
22 nov. 2017 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Reports Third Quarter 2017 Financial Results and Provides Corporate Update
08 nov. 2017 16h12 HE
|
Otonomy, Inc.
SAN DIEGO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX™ in Patients with Ménière's Disease
08 nov. 2017 16h05 HE
|
Otonomy, Inc.
Achieved primary endpoint (p value = 0.029)Company plans to meet with FDA to discuss results and clinical requirements for registrationManagement will review results during third quarter conference...